News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
New insights into TDP-43 mouse model pathophysiology
Earlier this year, we shared data from our phenotyping experiments showing TDP-43 mouse model pathophysiology, consistent with previously published findings in the same mouse model harboring the ALS-linked Q331K mutation in the TDP-43 gene (Watkins et al., 2021). Our...
InnoSer, Connected-Pathology, and Poulpharm Announce Strategic Partnership to Expand Preclinical and Histopathology Services
Together, the partners aim to enable seamless access to integrated multi-species expertise, focusing on advanced preclinical drug development and automated histopathology services, streamlining preclinical research for both human and veterinary drug development. ...
InnoSer and CureSHANK partner to launch industry-quality preclinical testing service for Phelan-McDermid syndrome (PMS) treatments
Together, CureSHANK, a nonprofit research foundation, and InnoSer, preclinical research CRO, aim to remove barriers to drug development for Phelan-McDermid syndrome treatment by providing the global research community with accessible and industry-standard preclinical...
Accelerating Angelman Syndrome Research: InnoSer now offers Angelman Syndrome Mouse Model
As part of our ongoing efforts to support the development of new therapeutics for rare genetic neurological diseases, we are proud to introduce a new preclinical research model for Angelman Syndrome within InnoSer’s portfolio. In collaboration with Professor Ype...
InnoSer Partners with Kabuki Syndrome Foundation to Advance Therapeutic Development for Kabuki Syndrome
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in the Kmt2d+/βGeo mouse model. This collaboration aims to empower leading biotech and pharma innovators to perform rigorous studies informing clinical trial readiness of...
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
info@innoserlaboratories.com